Jubilant Life Sciences raises Rs 495 crore via NCDs

28 Jan 2017 Evaluate

Jubilant Life Sciences has successfully completed issuance of non convertible debentures (NCDs) aggregating to Rs 495 crore for cash at par on a private placement basis. The issue comprises of 4 STRRPs payable in the second, third, fourth and fifth years such that the overall yield on the entire transaction is equivalent to 8.65% per annum, payable semi-annually.

The NCDs have been provisionally rated IND AA-/Stable by India Ratings and Research. The net proceeds of the issue shall be mainly used for refinancing of existing debt.

The company is engaged in manufacturing and supply of active pharmaceutical ingredient (APIs), solid dosage formulations, radio pharmaceuticals, allergy therapy products and life science ingredients. It also provides services in contract manufacturing of sterile injectables and ointments, creams and liquids and drug discovery and development.

Jubilant Pharmova Share Price

1043.20 -33.20 (-3.08%)
08-Dec-2025 15:31 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1790.05
Dr. Reddys Lab 1272.70
Cipla 1498.90
Zydus Lifesciences 920.90
Lupin 2061.50
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×